JP2021525531A5 - - Google Patents

Info

Publication number
JP2021525531A5
JP2021525531A5 JP2020567085A JP2020567085A JP2021525531A5 JP 2021525531 A5 JP2021525531 A5 JP 2021525531A5 JP 2020567085 A JP2020567085 A JP 2020567085A JP 2020567085 A JP2020567085 A JP 2020567085A JP 2021525531 A5 JP2021525531 A5 JP 2021525531A5
Authority
JP
Japan
Prior art keywords
vector
seq
nucleotide sequence
raav
shrna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020567085A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021525531A (ja
JP7563694B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/035159 external-priority patent/WO2019232517A1/en
Publication of JP2021525531A publication Critical patent/JP2021525531A/ja
Publication of JP2021525531A5 publication Critical patent/JP2021525531A5/ja
Application granted granted Critical
Publication of JP7563694B2 publication Critical patent/JP7563694B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020567085A 2018-06-01 2019-06-03 優性網膜色素変性症の処置のための組成物および方法 Active JP7563694B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862679585P 2018-06-01 2018-06-01
US62/679,585 2018-06-01
US201962809539P 2019-02-22 2019-02-22
US62/809,539 2019-02-22
PCT/US2019/035159 WO2019232517A1 (en) 2018-06-01 2019-06-03 Compositions and methods for treatment of dominant retinitis pigmentosa

Publications (3)

Publication Number Publication Date
JP2021525531A JP2021525531A (ja) 2021-09-27
JP2021525531A5 true JP2021525531A5 (enExample) 2022-06-13
JP7563694B2 JP7563694B2 (ja) 2024-10-08

Family

ID=68698456

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020567085A Active JP7563694B2 (ja) 2018-06-01 2019-06-03 優性網膜色素変性症の処置のための組成物および方法

Country Status (8)

Country Link
US (2) US12203074B2 (enExample)
EP (1) EP3802836A4 (enExample)
JP (1) JP7563694B2 (enExample)
CN (2) CN112204145B (enExample)
AU (1) AU2019276645B2 (enExample)
CA (1) CA3102095A1 (enExample)
IL (1) IL279091B1 (enExample)
WO (1) WO2019232517A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021212686A1 (zh) * 2020-04-21 2021-10-28 北京中因科技有限公司 RHO-adRP基于基因编辑的方法和组合物
JP7334346B2 (ja) * 2020-07-24 2023-08-28 アールズィーノミクス・インコーポレイテッド ロドプシン転写体に特異的なトランススプライシングリボザイム及びその用途
KR102396200B1 (ko) * 2020-07-24 2022-05-12 알지노믹스 주식회사 로돕신 전사체에 특이적인 트랜스-스플라이싱 라이보자임 및 이의 용도
WO2022073041A2 (en) * 2020-09-30 2022-04-07 NGGT, Inc. Dual functional expression vectors and methods of use thereof
WO2024211266A1 (en) * 2023-04-07 2024-10-10 University Of Houston System Downregulation of rhodopsin as a therapeutic strategy for peripherin-2-associated inherited retinal disorders

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040234999A1 (en) 1996-04-02 2004-11-25 Farrar Gwenyth Jane Genetic suppression and replacement
GB9606961D0 (en) 1996-04-02 1996-06-05 Farrar Gwyneth J Genetic strategy III
US8551970B2 (en) 1996-04-02 2013-10-08 Optigen Patents Limited Genetic suppression and replacement
AU2003268546A1 (en) * 2002-09-06 2004-03-29 Massachusetts Institute Of Technology Lentiviral vectors, related reagents, and methods of use thereof
AU2004233043A1 (en) 2003-04-18 2004-11-04 The Trustees Of The University Of Pennsylvania Compositions and methods for siRNA inhibition of angiopoietin 1 and 2 and their receptor Tie2
US20070009899A1 (en) 2003-10-02 2007-01-11 Mounts William M Nucleic acid arrays for detecting gene expression in animal models of inflammatory diseases
CN1977044A (zh) 2004-03-24 2007-06-06 肿瘤疗法科学股份有限公司 治疗胰腺癌的组合物和方法
US20080221057A1 (en) 2007-02-16 2008-09-11 Wyeth Secreted protein ccdc80 regulates adipocyte differentiation
EP2140004B1 (en) 2007-04-12 2022-01-12 The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin Genetic suppression and replacement
WO2009035792A1 (en) 2007-08-03 2009-03-19 Melba Ketchum Compositions, methods and systems for the simultaneous determination of parentage, identity, sex, genotype and/or phenotype and breed determination in animals
WO2010127209A2 (en) 2009-04-30 2010-11-04 The Research Foundation Of State University Of New York Compositions and methods for therapy of macular degeneration
CN102061308B (zh) 2010-10-29 2013-05-08 北京未名凯拓作物设计中心有限公司 一种用百草枯筛选转基因植物的方法
CN102061305B (zh) * 2010-12-15 2012-07-18 深圳市百恩维生物科技有限公司 一种多ShRNA高效协同沉默基因方法及载体
US20130064815A1 (en) 2011-09-12 2013-03-14 The Trustees Of Princeton University Inducing apoptosis in quiescent cells
US9695443B2 (en) 2012-05-25 2017-07-04 Commissariat A L'energie Atomique Et Aux Energies Alternatives Vector for the selective silencing of a gene in astrocytes
WO2014138792A1 (en) 2013-03-14 2014-09-18 Commonwealth Scientific And Industrial Research Organisation Double-stranded rna
WO2015075154A2 (en) 2013-11-20 2015-05-28 Fondazione Telethon Artificial dna-binding proteins and uses thereof
PL3628334T3 (pl) 2014-03-21 2023-12-18 Genzyme Corporation Terapia genowa w retinopatii barwnikowej
LT3137497T (lt) * 2014-05-02 2021-07-26 Genzyme Corporation Aav vektoriai, skirti tinklainės ir cns genų terapijai
AU2016222546B2 (en) * 2015-02-26 2020-01-23 Ionis Pharmaceuticals, Inc. Allele specific modulators of P23H rhodopsin
EP3748007B1 (en) 2015-03-06 2024-06-26 Massachusetts Eye & Ear Infirmary Gene augmentation therapies for inherited retinal degeneration caused by mutations in the prpf31 gene
EP3289080B1 (en) 2015-04-30 2021-08-25 The Trustees of Columbia University in the City of New York Gene therapy for autosomal dominant diseases
WO2017137493A1 (en) 2016-02-09 2017-08-17 Fondazione Telethon Synthetic promoters and uses thereof
US20170348387A1 (en) 2016-02-29 2017-12-07 The Trustees Of The University Of Pennsylvania Aav-mediated gene therapy for nphp5 lca-ciliopathy
CN115896106A (zh) 2016-03-01 2023-04-04 佛罗里达大学研究基金会有限公司 用于治疗显性视网膜色素变性的aav载体

Similar Documents

Publication Publication Date Title
JP2021525531A5 (enExample)
JP7651190B2 (ja) 遺伝子操作ｒｎａを用いた内因性ａｄａｒによる標的化ｒｎａ編集
JP7094236B2 (ja) 変異ａａｖ、及び、細胞、臓器並びに組織への遺伝子導入のための組成物、方法並びに使用法
JP2022517174A5 (enExample)
JP2022500066A5 (enExample)
JP2021502060A5 (enExample)
IL279091B1 (en) Compositions and methods for treating dominant retinitis pigmentosa
JP7546295B2 (ja) ヒトアンジェルマン症候群において父方ｕｂｅ３ａ遺伝子発現を復活させるための組成物および方法
JP2024119830A5 (enExample)
JP2023534037A5 (enExample)
CN113195719A (zh) 用于增加蛋白质表达和/或治疗单倍剂量不足症的方法及组合物
JP2021533801A5 (enExample)
JP2023532864A (ja) 導入遺伝子発現系
JP2023553005A5 (enExample)
JP2021534796A5 (enExample)
JP2023506842A5 (enExample)
US12415850B2 (en) Compositions and methods for regulating production of an antibody like protein and ribonucleic acid
EP4709862A2 (en) Rnai targeting kif1a missense mutations for treatment of kif1a associated neurological disorder
JP2023510186A5 (enExample)
WO2023172535A2 (en) shRNA TARGETING SNORD115 LOCATIONS TO RESTORE PATERNAL UBE3A GENE EXPRESSION IN ANGELMAN SYNDROME
WO2023172534A2 (en) shRNA TARGETING UBE3A-ATS TO RESTORE PATERNAL UBE3A GENE EXPRESSION IN ANGELMAN SYNDROME
JP2022508835A5 (enExample)
WO2025168955A1 (en) Therapy for dravet syndrome by targeting scn1a antisense transcript
WO2025065890A1 (zh) 一种重组腺相关病毒颗粒、重组腺相关病毒载体系统及其应用
WO2024254243A2 (en) Rnai targeting ppp2r5d missense mutations for treatment of jordan's syndrome